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Background:  In patients with severe aortic stenosis (AS) who are considered poor candidates for surgical aortic valve replacement (sAVR), 
transcatheter aortic valve implantation (TAVI) has demonstrated superiority over medical therapy / balloon valvuloplasty (BAV) in reduction of 1-year 
mortality. Currently TAVI is being evaluated against sAVR in patients with severe AS who are considered high-risk surgical candidates. This study 
aimed to detect the 1-year mortality rate of patients with severe AS who were screened for TAVI but treated with sAVR.
Methods:  From April 2007 to September 2010 a cohort of 134 patients with severe AS who were screen failures for the TAVI versus sAVR study 
were detected and referred for sAVR. Clinical follow-up of these patients was obtained by telephone contact or office visit.
Results:  The leading causes for screen failure to participate in the study were low Society of Thoracic Surgeons (STS) score <10%: 64 (47.7%), 
significant coronary artery disease: 20 (14.9%), aortic valve area >0.8 cm2: 8 (5.9%). The cohort mean age was 79.1±8.2, the STS score was 8.4±4.7, 
and the logistic EuroSCORE was 25.7±17.9. This cohort had many comorbidities with diabetes 45 (33.5%), coronary artery disease 80 (59.7%), 
cerebrovascular event 13 (9.7%), and renal failure 40 (29.8). The mean aortic valve area was 0.74±0.18cm2, mean gradient was 43.8±17.05 mmHg, 
and the mean ejection fraction was 54.9±14.7. During median follow up of 445[170-779] days the mortality rate was 26.9% (n=36).
Conclusion: The 1-year all-cause mortality rates recorded in patients with severe AS who are undergoing sAVR and who are at a lesser risk when 
compared with patients enrolled into the TAVI US trials are high. TAVI procedures should be considered as an alternative to sAVR in patients with 
slightly less risk to those who are being enrolled in US TAVI trials.
